oru.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Topoisomerase II-alpha expression in different cell cycle phases in fresh human breast carcinomas
Department of Oncology, Örebro University Hospital, Örebro, Sweden.
2Department of Pathology, Örebro University Hospital, Örebro, Sweden.
Department of Surgery, Örebro University Hospital, Örebro, Sweden.
Department of Medicine, Örebro University Hospital, Örebro, Sweden; Karolinska Institute, Stockholm, Sweden.
Show others and affiliations
2002 (English)In: Modern Pathology, ISSN 0893-3952, E-ISSN 1530-0285, Vol. 15, no 5, p. 486-491Article in journal (Refereed) Published
Abstract [en]

Topoisomerase II-alpha (topo II alpha) is the key target enzyme for the topoisomerase inhibitor class of anti-cancer drugs. In normal cells, topo II alpha is expressed predominantly in the S/G2/M phase of the cell cycle. In malignant cells, in vitro studies have indicated that the expression of topo II alpha is both higher and less dependent on proliferation state in the cell. We studied fresh specimens from 50 cases of primary breast cancer. The expression of topo II alpha in different cell cycle phases was analyzed with two-parameter flow cytometry using the monoclonal antibody SWT3D1 and propidium iodide staining. The expression of topo II alpha was significantly higher in the S/G2/M phase of the cell cycle than in the G0/G1 phase in both DNA diploid and DNA non-diploid tumors. In 18 of 21 diploid tumors, and in 25 of 29 non-diploid tumors, >50% of the topo II alpha-positive cells were in the G0/G1 phase. This significant expression of topo II alpha in the G0/G1 phase of the cell cycle may have clinically important implications for treatment efficacy of topoisomerase II inhibitors.

Place, publisher, year, edition, pages
Philadelphia, USA: Lippincott Williams & Wilkins, 2002. Vol. 15, no 5, p. 486-491
Keywords [sv]
Breast cancer, Ccell cycle, DNA flow cytometry, topoisomerase II alpha
National Category
Cancer and Oncology Clinical Laboratory Medicine
Identifiers
URN: urn:nbn:se:oru:diva-49512DOI: 10.1038/modpathol.3880552ISI: 000175665300002PubMedID: 12011253Scopus ID: 2-s2.0-0036092627OAI: oai:DiVA.org:oru-49512DiVA, id: diva2:914900
Available from: 2016-03-27 Created: 2016-03-25 Last updated: 2017-11-30Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records BETA

Tidefelt, UlfKarlsson, Mats G.

Search in DiVA

By author/editor
Tidefelt, UlfKarlsson, Mats G.
In the same journal
Modern Pathology
Cancer and OncologyClinical Laboratory Medicine

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 407 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf